Vancouver, BC, Canada - July 12, 2017, Vancouver, BC, Canada - DelMar Pharmaceuticals, a biopharmaceutical company, announced that Saiid Zarrabian has joined the company's board of directors and Erich Mohr has been elected to serve as its chairman.
Article continues below
Saiid Zarrabian comes to DelMar with over 30 years of senior executive or board member experience for multiple public and private companies.
Mr. Zarrabian is currently serving as an advisor to Redline Capital Partners, S.A., a Luxemburg based investment firm.
Mr. Zarrabian has previously served as Chairman and member of the Board of La Jolla Pharmaceutical Company during the company's transition from an OTC listed company to a successful NASDAQ listed company.
Mr. Zarrabian previously served as president of the Protein Production Division of Intrexon Corporation, as CEO & member of the Board of Cyntellect, as president and COO of Senomyx, as COO of Pharmacopeia where he also served as president & COO of its MSI Division.
In addition, he has served on numerous private and public company boards, including at Immune Therapeutics, Inc.; Exemplar Pharma, LLC; Ambit Biosciences Corporation; eMolecules, Inc.; and Penwest Pharmaceuticals CO.
Mr. Zarrabian's other experience includes COO at Molecular Simulations, COO of Symbolics, Inc., and as R&D Director at Computervision, Inc.
Erich Mohr has served as a director of DelMar since March 31, 2015 and has nearly two decades of biotechnology experience in executive leadership roles as co-founder, chief scientific officer, chief executive officer and board member, leading to well over a billion dollars of value creation.
Dr. Mohr has overseen and participated in dozens of clinical development programs and regulatory advisory panels.
Dr. Mohr is currently chairman, chief executive officer and founder of MedGenesis Therapeutix.
Formerly, he was chairman and chief executive officer of CroMedica Global which merged with PRA International in 2002 to form one of the major contract research organizations in the world.
In addition to his industry experience, Dr. Mohr has over 30 years of academic experience in experimental therapeutics of CNS disorders including eight years at the University of Ottawa, ultimately as a Professor of Medicine (Neurology) and Psychology.
Dr. Mohr is the author of over 150 publications, books, book chapters and abstracts.
He is the former chair of the Board of Governors of the University of Victoria. ■